In May 2022, 1% tapinarof was FDA-approved for mild-to-moderate adult plaque psoriasis [100], making it the first-in-class AHR modulating drug, as well as the first novel topical treatment for psoriasis developed in 25 years [100]. Here, AHR is linked to psoriasis.